A novel peptide derived from a marine fish can penetrate mammalian cells with minimal toxicity and selectively kill methicillin-resistant Staphylococcus aureus (MRSA).
5 μM uptakeEngraulisin successfully penetrated mammalian cells at just 5 micromolar concentration with negligible toxicity, while also killing MRSA
What the researchers found
Engraulisin demonstrated successful cellular uptake in mammalian cells at 5 μM with negligible cytotoxicity (MTT assay). It entered cells primarily via endocytosis. The peptide showed selective antimicrobial activity against MRSA. Molecular dynamics simulations revealed positively charged residues form stable interactions with bacterial membrane models (POPC and POPG bilayers).
Why it matters
Antimicrobial resistance is a global health crisis, with MRSA infections causing tens of thousands of deaths annually. Cell-penetrating peptides that can also kill resistant bacteria represent a dual-function therapeutic platform — they could both deliver drugs inside cells and directly combat infections.
The numbers in context
Not specified in abstract — characterization and activity study.
How the study worked
Computational peptide design from Engraulis japonicus protein sequences, followed by in vitro validation. Cell uptake confirmed via fluorescence microscopy in mammalian cells. Cytotoxicity assessed by MTT assay. Uptake mechanism probed by temperature inhibition (4°C). Antimicrobial activity tested against drug-resistant bacteria. Molecular dynamics simulations with POPC and POPG membrane bilayers analyzed peptide-membrane interactions.
Who was studied
In vitro antimicrobial testing against drug-resistant bacteria
What this study cannot tell us
In vitro study only — no animal or human testing. Antimicrobial activity shown only against MRSA; spectrum against other pathogens unclear. No minimum inhibitory concentration (MIC) values reported in the abstract. Stability, bioavailability, and in vivo efficacy unknown. Computationally designed — real-world therapeutic development requires extensive further validation.
How to read the evidence
Rated preliminary: in vitro and computational study demonstrating proof-of-concept. No animal or human data, and no MIC values reported for antimicrobial activity.
When this study was published
Published in 2024. Represents early-stage discovery of a novel marine peptide with dual cell-penetrating and antimicrobial functions.
The bigger picture
Marine organisms evolved in harsh environments and harbor peptides with unique properties rarely found in terrestrial species. Engraulisin adds to the growing arsenal of marine-derived peptides and demonstrates how computational approaches can accelerate discovery of peptides with multiple useful functions.
Questions still open
- Can Engraulisin be used to deliver antibiotics directly inside MRSA-infected cells for enhanced killing?
- What is the peptide's stability in blood and tissue — would it survive long enough to reach infection sites?
- Could similar marine-derived peptides be effective against other drug-resistant pathogens like vancomycin-resistant enterococci?
Common questions
What is a cell-penetrating peptide?
Can peptides from fish fight antibiotic-resistant infections?
Read the original research
Engraulisin: A novel marine derived cell penetrating peptide with activity against drug resistant bacteria.
Biochimica et biophysica acta. Biomembranes, 1866(2), 184255
Citation
Saraswat, Saurabh; Chugh, Archana. (2024). Engraulisin: A novel marine derived cell penetrating peptide with activity against drug resistant bacteria.. Biochimica et biophysica acta. Biomembranes, 1866(2), 184255. https://doi.org/10.1016/j.bbamem.2023.184255